Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of CEP-1347 in Icelandic patients with asthma
2004-002812-27Phase 2Completed
- Sponsor
- deCODE genetics ehf.
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CEP1347 in asthma (4 arms), sponsored by deCODE genetics ehf. Primary endpoints: Safety and tolerability of CEP-1347 and Efficacy of CEP-1347 in asthma. Started Apr 2005; status: completed.
02
Drugs
CEP1347
03
Conditions
asthma
Beyond the preview
Go deeper on 2004-002812-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002812-27.